The Heart Valve Program at CHI Memorial offers a revolutionary procedure for the treatment of aortic valve stenosis for patients who previously weren’t candidates for surgical valve replacement.
Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive procedure that enables a collapsible aortic heart valve to be placed inside the heart. The Edwards SAPIEN Valve is the first TAVR therapy to receive FDA approval. CHI Memorial performed the third implant in the nation using the FDA approved SAPIEN device.
During the minimally invasive procedure, the TAVR device is crimped down to the size of a pencil and then placed into the body via a catheter that is inserted in an artery in the upper thigh. Once it’s delivered to the site of the patient’s diseased valve, the device is expanded with a balloon and begins to work immediately.
The most exciting aspect of this procedure is that it provides hope when there were no previous options. For those patients who aren’t surgical candidates and have severe symptomatic aortic stenosis, studies show that without some type of intervention, 50% of patients don’t survive more than an average of two years. The transcatheter valve offers some patients the potential of a longer life and better quality as well.
To assess whether someone is a candidate for the transcatheter valve, patients with severe aortic valve disease are screened in CHI Memorial Hospital’s Heart Valve Program. This program is directed by a team of specially trained cardiovascular surgeons, interventional cardiologists, and imaging cardiologists who review possible candidates to determine if the TAVR is the best course of treatment for each individual patient.
To learn more about CHI Memorial’s Heart Valve Program, patients may discuss their condition with their physician or call the Heart Valve Program at (423) 495-4327.